Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aesculaap BvfiledCriticalAesculaap Bv
Publication of MX9709860ApublicationCriticalpatent/MX9709860A/en
Publication of MXPA97009860ApublicationCriticalpatent/MXPA97009860A/en
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
This invention describes that apoptin fails to induce apoptosis in human normal cells. Besides, the invention describes that when normal cells are transformed, they become susceptible to the apoptin-induced apoptosis. The invention describes that apoptin induces in various human tumor cells a p53-distinct type of apoptosis, and cannot be blocked by a variety of apoptosis-inhibiting agents. The invention comprises an anti-tumor agent, which specifically kill tumor and not normal cells. It further provides the induction of cell death by means of gene therapy. Apoptin can induce apoptosis in non-human animal tumor cells. The invention also provides that in normal cells apoptin was found predominantly in the cytoplasm, while in tumor cells it was located in the nucleus. Besides, the invention comprises a diagnostic test for the determination of cell-transforming activity.
MXPA/A/1997/009860A1995-06-071997-12-08Methods and uses for apopt
MXPA97009860A
(en)
The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells